Residual CFTR function in cystic fibrosis was associated with better glucose tolerance and insulin secretion, with CFTR ...
Sionna Therapeutics, Inc. has announced the presentation of promising preclinical data at the 48th European Cystic Fibrosis Conference in Milan, showing that its nucleotide-binding domain 1 (NBD1) ...
Cystic fibrosis (CF) remains an exemplar of how detailed molecular understanding can fuel transformative advances in treatment. Research in this field spans elucidating the genetic and cellular ...
WALTHAM, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for ...
Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and often overlooked complication. A groundbreaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback